Communications Biology · 2022 · 53 citations · 32 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCancer Stem CellsGlioblastomaImmunotherapy For Brain TumorsNatural Killer Cell BiologyNatural Killer Cell TherapyCancer Stem-like CellsGlioblastoma ImmunotherapyGlioblastoma Stem CellsGlioblastoma Therapeutic ResistanceGlioblastoma Tumor MicroenvironmentMhc Class I MoleculesNatural Killer Cell-based Cancer ImmunotherapyTherapy-resistant Cancer Stem Cells
Glioblastomas remain the most lethal primary brain tumors. Natural killer (NK) cell-based therapy is a promising immunotherapeutic strategy in the treatment of glioblastomas, since these cells can select and lyse therapy-resistant glioblastoma stem-like cells (GSLCs). Immunotherapy with super-charged NK cells has a potential as antitumor approach since we found their efficiency to kill patient-derived GSLCs in 2D and 3D models, potentially reversing the immunosuppression also seen in the patients. In addition to their potent cytotoxicity, NK cells secrete IFN-γ, upregulate GSLC surface expression of CD54 and MHC class I and increase sensitivity of GSLCs to chemotherapeutic drugs. Moreover, NK cell localization in peri-vascular regions in glioblastoma tissues and their close contact with GSLCs in tumorospheres suggests their ability to infiltrate glioblastoma tumors and target GSLCs. Due to GSLC heterogeneity and plasticity in regards to their stage of differentiation personalized immunotherapeutic strategies should be designed to effectively target glioblastomas.
32
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao, Qiulian Wu, Roger E. McLendon et al. · Nature · 2006 · 6.4K citations
Medicine, Cancer Biology, Oncology +16
Fadi Jacob, Ryan Salinas, Daniel Y. Zhang et al. · Cell · 2019 · 1.1K citations · Full text
Medicine, Cancer Biology, Oncology +16